More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

In our January 14 blog, we explained that Chief Judge Lance Walker of the U.S. District Court for the District of Maine had entered a nationwide preliminary injunction in American Hospital Association ...

Amid barbs over the shutdown and broader healthcare funding cuts, a Thursday committee hearing brought bipartisan agreement that more can be done to ensure the pricey drug subsidy program remains a ...

Free market think tank Heartland Impact will soon launch a new ad campaign urging Kansas lawmakers to end the waste, fraud and abuse prevalent in the 340B hospital system ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo: Shopify Partners / Burst (The Center Square) – Hospitals and clinics in Michigan participating in a federal drug discount ...

A federal judge handed down a decision this week in a lawsuit involving the 340B prescription drug discount program as hospitals, physicians, and drug manufacturers continue to battle over how the ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

A federal appeals court has dealt a blow to pharmaceutical manufacturers' attempts to restructure the 340B drug discount program -- a decision that preserves billions of dollars in savings for ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Unexpected windfall or fragile safety net? Affluent communities or vulnerable poor? Welfare check or supplemental provider program? Making sense of the latest 340B program study published by the ...